In 2026, Skye is focused on defining the optimal dose and development path for nimacimab as an add-on to GLP-1 therapies like semaglutide. Priorities include generating higher-dose safety and PK data, enabling subcutaneous dosing, and finalizing Phase 2b.
ir.skyebioscience.com
#Biotech #Obesity
Skye Bioscience will be presenting at the upcoming GLP-1-Based Therapeutics Summit, a leading forum focused on advancing next-generation therapies in obesity and metabolic disease. We look forward to engaging with the scientific and clinical community.
ir.skyebioscience.com/news-release...
Skye is taking the next step to better understand nimacimab’s potential. An expansion of the CBeyond study will evaluate higher doses. The goal is to define the dose-efficacy relationship, confirm safety at higher exposure levels, and inform Phase 2b dose selection.
ir.skyebioscience.com
#Biotech
Skye continues to build on its approach to optimizing dose and exposure of nimacimab. We treated the first patient in our higher-dose CBeyond Expansion Study, designed to evaluate the relationship between exposure and safety and inform Phase 2b dose selection. ir.skyebioscience.com/news-release...
Skye is advancing nimacimab with a clear focus: Optimizing dose and exposure to unlock its full potential. In our CBeyond study, nimacimab demonstrated results in combination with semaglutide. Higher exposure may be needed to engage peripheral CB1 targets.
ir.skyebioscience.com
#Biotech #Obesity
Skye continues to advance nimacimab as a potential differentiated therapy for obesity. Progress includes initiating the CBeyond Expansion Study and implement FDA feedback to guide Phase 2b planning.
Read more at: ir.skyebioscience.com/news-releases
#Biotech #Obesity
Today, Skye reported its financial results for the fourth quarter and full year ended December 31, 2025 while also sharing a business update highlighting recent achievements and important milestones ahead.
Read the release: ir.skyebioscience.com/news-release...
#Biotech #Obesity
Reminder: Join us today at 4:30 p.m. ET / 1:30 p.m. PT for Skye Bioscience’s webcast to discuss our fourth quarter and full year 2025 financial results and business update.
The webcast will be available through our Investor Relations website: ir.skyebioscience.com/company-info...
#BioTech #Obesity
Join us on March 10, 2026, as Skye Bioscience reports its 2025 fourth quarter and full-year financial results and provides a corporate update.
Read the press release here: ir.skyebioscience.com/news-release...
#Biotech #Obesity
Skye reports positive interim CBeyond™ Phase 2a extension results, with 22.3% average total weight loss at 52 weeks for nimacimab in combination with semaglutide. Read the full release:
ir.skyebioscience.com/news-release...
#Biotech #Obesity
Skye presented new data at the Keystone Symposium on Obesity, highlighting key attributes of nimacimab, our peripherally restricted CB1 inhibitor antibody. View the poster: skyebioscience.com/keystone-202...
Skye Bioscience will be presenting a poster at the Keystone Obesity Conference. The presentation highlights ongoing scientific work supporting our focus in metabolic disease.
Read the press release here: ir.skyebioscience.com/news-release...